HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors
Open accessThe DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index.
Abstract
Since the human immunodeficiency virus (HIV) was discovered as the etiological agent of acquired immunodeficiency syndrome (AIDS), it has encouraged much research into antiviral compounds. The reverse transcriptase (RT) of HIV has been a main target for antiviral drugs. However, all drugs developed so far inhibit the polymerase function of the enzyme, while none of the approved antiviral agents inhibit specifically the necessary ribonuclease H (RNase H) function of RT. This review provides a background on structure-function relationships of HIV-1 RNase H, as well as an outline of current attempts to develop novel, potent chemotherapeutics against a difficult drug target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. A Crystal structure of HIV-1 RT (PDB code: 1RTD. The p51 subunit is shown in orange, while the p66 subunit is divided into the fingers (cyan), connection (blue) and RNase H (grey) subdomains. The residues of the conserved DEDD motif are shown and red and marked with arrows. B Crystal structures of the RNase H domain of HIV-1 RT (PDB code:1RTD) [5], human RNase H1 (PDB code: 2QKB) [12] and E. coli RNase H1 (PBD code: 1WSJ). All three show the same mixed beta-sheet with asymmetric alpha helices, while the human and E. coli RNases H contain the C-helix, or basic loop.](https://figures.cochat.ai/paper-figures/b63df9a426c04092bf0ff917330c098e/hiv-1-ribonuclease-h-structure-catalytic-mechanism-and-inhibitors-figure-2.jpg)



![Figure 6. A During (−)-strand DNA synthesis, the PPT region of the RNA genome is resistant to RNase H cleavage, while a portion of the RNA genome is degraded concomitantly with (−)-strand DNA synthesis. Here, a specific cleavage is made to create the PPT primer. B The RNase H-resistant PPT sequence forms the primer for (+)-strand DNA synthesis when the rest of the genome is completely degraded by RNase H. C The RNA primer is extended 12 nucleotides, D then RT pauses and changes orientations to a polymerase-independent binding mode in order to cleave at the DNA:RNA junction, and remove the PPT primer. E The 12-mer fragment is extended toward the 5′ end of the (−)-strand DNA (see Figure 1F). After the second strand transfer event, the (+)-strand DNA is fully synthesized resulting in a fully double-stranded provirus. Adapted from [49].](https://figures.cochat.ai/paper-figures/20a118ca091245829bbec2fa00a9968d/hiv-1-ribonuclease-h-structure-catalytic-mechanism-and-inhibitors-figure-6.jpg)
![Figure 7. Examples of the main classes of small molecule inhibitors against HIV-1 RT-associated RNase H activity. A N-hydroxyimides. Developed from influenza inhibitors and among the first to use the 3-oxygen pharmacophore [84]. B Pyrimidinol carboxylic acid derivatives [85]. Potent inhibitors based on the successful scaffold of the metal-chelating active site inhibitors. C Diketo acid derivatives are also active in some cases against the viral integrase. RDS1643 shown here is the only diketo acid to have antiviral activity in vivo [86]. D The vinylogous ureas (NSC727447 pictured here) represent a different kind of inhibitor that binds allosterically near the p51 thumb [87]. E N-acyl hydrazones appear to bind to multiple binding sites depending on the specific inhibitor, including the RNase H domain and a site that overlaps the NNRTI binding pocket (DHBNH picture above) [88]. F Hydroxylated tropolones (β-thujaplicinol pictured here) are the subject of several studies that have provided the basis for a biochemical mechanism of inhibition by active site RNase H inhibitors [39,89,90].](https://figures.cochat.ai/paper-figures/3e3e02f115734f71b03c1cf5be0d88d9/hiv-1-ribonuclease-h-structure-catalytic-mechanism-and-inhibitors-figure-7.jpg)
![Figure 8. A schematic of possible models of active site inhibitor binding, based on studies with the tropolone derivative β-thujaplicinol (blue sphere) [39,90]. Evidence suggests that the inhibitor is unable to bind to an enzyme-substrate (E-S) complex (top left), only to free enzyme forming (top right) and enzyme-inhibitor (E-I) complex (bottom right). However, the substrate might be able to bind to this E-I complex, forming an E-S-I complex that is not productive with respect to RNase H cleavage (bottom left). As suggested by Himmel et al., the inhibitor occupies the position normally claimed by the scissile phosphate [90]. As such, it is possible that the substrate undergoes a change in trajectory in relation to the scissile phosphate and the RNase H active site [39]. Then eventually, the inhibitor dissociates and RT is allowed to cleave the uninhibited substrate (E-S complex, top left).](https://figures.cochat.ai/paper-figures/1c9b6865dd434338935d8adfac6655d4/hiv-1-ribonuclease-h-structure-catalytic-mechanism-and-inhibitors-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Based on these structural and functional experiments, the two metal-binding mechanism has been widely accepted [27,28,30,31,63,64].”
From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [30]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914 · cited 1×
“the non-nucleoside binding pocket, a hydrophobic depression created by the binding of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and located near the base of the p66 thumb subdomain, about 10 Å from the polymerase active site [4,64,65].”
BackgroundHuang, H., Chopra, R., Verdine, G. L., & Harrison, S. C. (1998) · Science · doi:10.1126/science.282.5394.1669 · Cited by 1,420
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“Diketo acids also form a group of compounds initially developed against the structurally similar HIV-1 integrase (IN) [92,93].”
BackgroundJacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., et al. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6320 · Cited by 1,115 · cited 2×
“B-form geometry near the RNase H active site [6].”
BackgroundAnti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq, E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.10.010 · Cited by 627 · cited 2×
“There are currently 25 compounds in clinical use to treat HIV [2].”
BackgroundNowotny, M., Gaidamakov, S. A., Crouch, R. J., & Yang, W. (2005) · Cell · doi:10.1016/j.cell.2005.04.024 · Cited by 620 · cited 3×
“halodurans ) [9-11] and eukaryotic (human) [12] RNases H, and is part of the superfamily of polynucleotidyl transferases.”
BackgroundMaking and Breaking Nucleic Acids: Two-Mg2+-Ion Catalysis and Substrate Specificity
Yang, W., Lee, J. Y., & Nowotny, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.013 · Cited by 573 · cited 1×
“This has led to the general acceptance of a two-metal ion mechanism for retroviral RNase H hydrolysis [11,12,17].”
BackgroundCrystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase
Davies, J. F., Hostomska, Z., Hostomsky, Z., Jordan, S. R., & Matthews, D. A. (1991) · Science · doi:10.1126/science.1707186 · Cited by 570 · cited 2×
“In the case of HIV-1 RT, the RNase H domain constitutes the C-terminus of the p66 subunit, which is missing in p51, due to cleavage by the viral protease [3-7].”
BackgroundHigh resolution structures of HIV-1 RT from four RT–inhibitor complexes
Ren, J., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., Darby, G., Jones, Y., Stuart, D., et al. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0495-293 · Cited by 502 · cited 1×
“the non-nucleoside binding pocket, a hydrophobic depression created by the binding of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and located near the base of the p66 thumb subdomain, about 10 Å from the polymerase active site [4,64,65].”
BackgroundMechanism and fidelity of HIV reverse transcriptase.
Kati, W. M., Johnson, K. A., Jerva, L. F., & Anderson, K. S. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35706-5 · Cited by 492 · cited 1×
“In the presence of deoxyribonucleotides (dNTPs) RT will advance and RNase H will eventually continue to cut the template; however, the rate of RNase H cleavage is approximately seven times slower than polymerization [33].”
Background
Research works printed but not linked: 1
- Telesnitsky, A., and Goff, S. (1997). Cold Spring Harbor Laboratory Press.
Cited by
Menéndez-Arias, L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.01.007 · Cited by 207
RNases H: Structure and mechanism
Hyjek, M., Figiel, M., & Nowotny, M. (2019) · DNA Repair · doi:10.1016/j.dnarep.2019.102672 · Cited by 160
Vernekar, S. K. V., Liu, Z., Nagy, E., Miller, L., Kirby, K. A., Wilson, D. J., Kankanala, J., Sarafianos, S. G., Parniak, M. A., & Wang, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501132s · Cited by 137
Menéndez-Arias, L., Sebastián-Martín, A., & Álvarez, M. (2017) · Virus Research · doi:10.1016/j.virusres.2016.12.019 · Cited by 123
Esposito, F., Corona, A., & Tramontano, E. (2012) · Molecular Biology International · doi:10.1155/2012/586401 · Cited by 138
“This action occurs through the deprotonation of a water molecule, with the production of a nucleophilic hydroxide group that attacks the scissile phosphate group on the RNA previously activated by coordination with the Mg cofactor [24].”
BackgroundAvoiding drug resistance in HIV reverse transcriptase
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00967 · Cited by 106
Louten, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800947-5.00004-1 · Cited by 80
Das, K., Martinez, S. E., Bandwar, R. P., & Arnold, E. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku487 · Cited by 68
“Biochemical studies have revealed that RT degrades the RNA strand by combinations of primer-dependent primary cuts and primerindependent secondary cuts (11); see reviews by Schultz and Champoux (12) and Beilhartz and Gotte (13).”
BackgroundEsposito, F., & Tramontano, E. (2014) · Antiviral Chemistry and Chemotherapy · doi:10.3851/imp2690 · Cited by 68
Advantages of Ion-Exchange Chromatography for Oligonucleotide Analysis
Cook, K., & Thayer, J. R. (2011) · Bioanalysis · doi:10.4155/bio.11.66 · Cited by 70
Todd, B., Tchesnokov, E. P., & Götte, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100486 · Cited by 50
“The described circumstances are reminiscent of the mechanism of action of HIV-1 RNase H inhibitors (22, 36, 37).”
BackgroundMethodSelf-citationTang, J. Y., Liu, F., Nagy, E., Miller, L., Kirby, K. A., Wilson, D. J., Wu, B., Sarafianos, S. G., Parniak, M. A., & Wang, Z. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01879 · Cited by 49
Kankanala, J., Kirby, K. A., Huber, A. D., Casey, M. C., Wilson, D. J., Sarafianos, S. G., & Wang, Z. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.054 · Cited by 44
“domains [27], inhibition of RNase H is often accompanied by the inhibition of RT pol.”
Vernekar, S. K. V., Tang, J., Wu, B., Huber, A. D., Casey, M. C., Myshakina, N., Wilson, D. J., Kankanala, J., Kirby, K. A., Parniak, M. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00440 · Cited by 41
“13 Chemotypes known for active site RNase H inhibition include 2-hydroxyisoquinolinedione (HID, 1),14-16 β-thujaplicinol (2),17 dihydroxycoumarin (3),18 diketoacid (4),19 pyrimidinol carboxylic acid (5),20 hydroxynaphthyridine (6)21 and pyridopyrimidone 7.”
BackgroundWang, L., Sarafianos, S. G., & Wang, Z. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00450 · Cited by 43
Mousseau, G., Aneja, R., Clementz, M. A., Mediouni, S., Lima, N. S., Haregot, A., Kessing, C. F., Jablonski, J. A., Thenin-Houssier, S., Nagarsheth, N., et al. (2019) · mBio · doi:10.1128/mbio.01750-18 · Cited by 47
Developing and Evaluating Inhibitors against the RNase H Active Site of HIV-1 Reverse Transcriptase
Boyer, P. L., Smith, S. J., Zhao, X. Z., Das, K., Gruber, K., Arnold, E., Burke, T. R., & Hughes, S. H. (2018) · Journal of Virology · doi:10.1128/jvi.02203-17 · Cited by 38
“secondary cleavages but have little or no effect on the primary cleavages (3, 4).”
BackgroundWang, L., Tang, J., Huber, A. D., Casey, M. C., Kirby, K. A., Wilson, D. J., Kankanala, J., Xie, J., Parniak, M. A., Sarafianos, S. G., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.039 · Cited by 36
“HIV RT has two distinct domains[3]: a pol domain which carries out both RNA-dependent and DNA-dependent viral DNA polymerization and is targeted by all currently known nucleoside RT inhibitors (NRTIs)[4] and non-nucleoside RT inhibitors (NNRTIs)[5]; and an RNase H domain[3, 6] which is required to degrade the RNA stra…”
BackgroundTechnologies for Targeted RNA Degradation and Induced RNA Decay
Mikutis, S., & Bernardes, G. J. L. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00472 · Cited by 36
Felts, A. K., LaBarge, K., Bauman, J. D., Patel, D. V., Himmel, D. M., Arnold, E., Parniak, M. A., & Levy, R. M. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200194w · Cited by 37
Gawali, R. G., Trivedi, J. S., Bhansali, S. G., Bhosale, R. B., Sarkar, D. M., & Mitra, D. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.067 · Cited by 36
Small Molecule Drugs Targeting Viral Polymerases
Palazzotti, D., Sguilla, M., Manfroni, G., Cecchetti, V., Astolfi, A., & Barreca, M. L. (2024) · Pharmaceuticals · doi:10.3390/ph17050661 · Cited by 35
“The polymerase domain is composed of three subdomains: palm (residues 86–117 and 156–236), fingers (residues 1–85 and 118–155), and thumb (237–318) [100,101] (Figure 4).”
BackgroundCoordination between the polymerase and RNase H activity of HIV-1 reverse transcriptase
Figiel, M., Krepl, M., Poznański, J. T., Gołąb, A., Šponer, J., & Nowotny, M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx004 · Cited by 36
“An indication of such a simultaneous interaction, although not explicit, was provided by studies using RT-RNA/DNA complexes in which the substrate was stabilized at the polymerase active site through binding of the pyrophosphate analog inhibitor (35).”
MethodLi, A., Li, J., & Johnson, K. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753160 · Cited by 33
“Reverse transcription of HIV is a complex process that converts the single-stranded RNA genome of the virus into doublestranded DNA (29) and requires a close coordination between the RNA-dependent polymerase and the RNase H, which degrades the RNA during minus-strand DNA synthesis to allow template switching and effic…”
BackgroundWang, L., Tang, J. Y., Huber, A. D., Casey, M. C., Kirby, K. A., Wilson, D. J., Kankanala, J., Parniak, M. A., Sarafianos, S. G., & Wang, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.035 · Cited by 32
Kirby, K. A., Marchand, B., Ong, Y. T., Ndongwe, T. P., Hachiya, A., Michailidis, E., Leslie, M. D., Sietsema, D. V., Fetterly, T. L., Dorst, C. A., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06000-11 · Cited by 35
“Unlike the gammaretroviral RTs, HIV-1 RT lacks -helix C in the RNase H domain, which is thought to be important for substrate binding (5, 26, 39, 51, 52), as the p15 RNase H domain of HIV-1 RT has no enzymatic activity (81, 82, 97).”
BackgroundBeilhartz, G. L., Ngure, M., Johns, B. A., DeAnda, F., Gerondelis, P., & Götte, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.569707 · Cited by 28
“Several distinct chemical compounds with a three-oxygen pharmacophore, or equivalent structures that are capable of chelating the two catalytic metal ions have been described (20, 21).”
BackgroundSelf-citationTang, J. Y., Do, H. T., Huber, A. D., Casey, M. C., Kirby, K. A., Wilson, D. J., Kankanala, J., Parniak, M. A., Sarafianos, S. G., & Wang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.081 · Cited by 28
Overacker, R. D., Banerjee, S., Neuhaus, G. F., Sephton, S. M., Herrmann, A., Strother, J. A., Brack‐Werner, R., Blakemore, P. R., & Loesgen, S. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.06.044 · Cited by 27
Latanova, A. A., Petkov, S., Kilpeläinen, A., Jansons, J., Latyshev, O., Kuzmenko, Y. V., Hinkula, J., Abakumov, M. A., Треворович, В.-Э. В., Gomelsky, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26281-z · Cited by 26
Real time monitoring of junction ribonuclease activity of RNase H using chimeric molecular beacons
Liu, B., Xiang, D., Long, Y., & Tong, C. (2013) · The Analyst · doi:10.1039/c3an36414c · Cited by 26
Kirby, K. A., Myshakina, N. S., Christen, M. T., Chen, Y.-L., Schmidt, H. A., Huber, A. D., Xi, Z., Kim, S., Rao, R. K., Kramer, S. T., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01351-17 · Cited by 22
“double-stranded DNA for downstream incorporation into the host cell genome (1).”
BackgroundIntegrative approaches in HIV ‐1 non‐nucleoside reverse transcriptase inhibitor design
Poongavanam, V., Namasivayam, V., Vanangamudi, M., Shamaileh, H. A., Veedu, R. N., Kihlberg, J. O., & Murugan, N. A. (2017) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1328 · Cited by 24
Current medicinal chemistry strategies in the discovery of novel HIV-1 ribonuclease H inhibitors
Zhang, L., Wei, F., Zhang, J., Liu, C., López‐Carrobles, N., Liu, X., Menéndez‐Arias, L., & Zhan, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114760 · Cited by 21
Messore, A., Corona, A., Madia, V. N., Saccoliti, F., Tudino, V., Leo, A. D., Ialongo, D., Scipione, L., Vita, D. D., Amendola, G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00535 · Cited by 17
Tong, C., Zhou, T., Zhao, C., Yuan, L., Xu, Y. C., Liu, B., Fan, J., Li, D., & Zhu, A. (2019) · Microchimica Acta · doi:10.1007/s00604-019-3425-6 · Cited by 15
Homodimerisation-independent cleavage of dsRNA by a pestiviral nicking endoribonuclease
Lussi, C., Sauter, K., & Schweizer, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-26557-4 · Cited by 14
Retroviral RNase H: structure, mechanism, and inhibition
(2021) · The Enzymes · doi:10.1016/bs.enz.2021.07.007 · Cited by 13
The Impact of RNA-DNA Hybrids on Genome Integrity in Bacteria
McLean, E. K., Nye, T. M., Lowder, F. C., & Simmons, L. A. (2022) · Annual Review of Microbiology · doi:10.1146/annurev-micro-102521-014450 · Cited by 14
Sheet, S. K., Rabha, M., Sen, B., Patra, S. K., Aguan, K., & Khatua, S. (2021) · ChemBioChem · doi:10.1002/cbic.202100229 · Cited by 13
Bruccoleri, A. G. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0141 · Cited by 13
“The absence of tyrosine residues 181 and 188 in HIV-2 RT explains the lack of effect of NNRTIs on this RT.39 Although Tyr-181 and Tyr-188 lie within a conserved motif, they are not essential for the polymerase activity.”
BackgroundInfluentialZhu, X.-D., Corona, A., Maloccu, S., Tramontano, E., Wang, S., Pannecouque, C. C., Clercq, E. D., Meng, G., & Chen, F. (2024) · Molecules · doi:10.3390/molecules29092120 · Cited by 12
“Despite extensive efforts to produce RNase H inhibitors, no The potential of HIV RT-associated RNase H as a therapeutic target has yet to be fully explored [21–23].”
BackgroundLatanova, A. A., Petkov, S., Kuzmenko, Y. V., Kilpeläinen, A., Ivanov, A. V., Smirnova, O. A., Krotova, O., Korolev, S. P., Hinkula, J., Карпов, В. Л., et al. (2017) · Journal of Immunology Research · doi:10.1155/2017/7407136 · Cited by 11
TEMPLATE-DIRECTED BIOPOLYMERIZATION: TAPE-COPYING TURING MACHINES
Sharma, A. K., & Chowdhury, D. (2012) · Biophysical Reviews and Letters · doi:10.1142/s1793048012300083 · Cited by 11
Yoon, J., Lee, J., Kim, J., Lee, S. M., Kim, S., & Park, H. G. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116174 · Cited by 10
Metal and ligand binding to the HIV-RNase H active site are remotely monitored by Ile556
Zheng, X., Mueller, G. A., DeRose, E. F., & London, R. E. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks791 · Cited by 10
Tannous, E., Yokoyama, K., You, D., Koga, Y., & Kanaya, S. (2012) · FEBS Open Bio · doi:10.1016/j.fob.2012.10.003 · Cited by 11
“The RNase H activity of human immunodeficiency virus (HIV) is therefore regarded as a target for AIDS therapy [5].”
BackgroundAsthana, A., Corona, A., Shin, W.-J., Kwak, M.-J., Gaughan, C., Tramontano, E., Jung, J. U., Schobert, R., Jha, B. K., Silverman, R. H., et al. (2023) · Viruses · doi:10.3390/v15071539 · Cited by 9
A hybrid chimeric system for versatile and ultra-sensitive RNase detection
Persano, S., Vecchio, G., & Pompa, P. P. (2015) · Scientific Reports · doi:10.1038/srep09558 · Cited by 9
Kharkwal, H., Kumar, B. K., Murugesan, S., Singhvi, G., Avasthi, P., Goyal, A., Jamalis, J., & Chander, S. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0257 · Cited by 8
Developing New Tools to Fight Human Pathogens: A Journey through the Advances in RNA Technologies
Costa, V., Costa, S. M., Saramago, M., Cunha, M. V., Arraiano, C. M., Viegas, S. C., & Matos, R. G. (2022) · Microorganisms · doi:10.3390/microorganisms10112303 · Cited by 9
Zhang, L., Wei, F., Borrego, D., Zhao, F., del Río, J. M., Frutos-Beltrán, E., Zhang, J., Xu, S., López‐Carrobles, N., Gao, S., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114563 · Cited by 8
Martin, J. A., Robustelli, P., & Palmer, A. G. I. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00500 · Cited by 6
Liao, Z., Oyama, T., Kitagawa, Y., Katayanagi, K., Morikawa, K., & Oda, M. (2022) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798322000870 · Cited by 6
Karki, I., Christen, M. T., Spiriti, J., Slack, R. L., Oda, M., Kanaori, K., Zuckerman, D. M., & Ishima, R. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b08323 · Cited by 5
Mahajan, P. S., Smith, S. J., Hughes, S. H., Zhao, X. Z., & Burke, T. R. (2023) · Molecules · doi:10.3390/molecules28031428 · Cited by 5
Reverse Transcriptase and Retroviral Replication
Matamoros, T., Álvarez, M., Barrioluengo, V., Betancor, G., & Menéndez‐Arias, L. (2011) · InTech eBooks · doi:10.5772/21660 · Cited by 7
“Other RNase H inhibitors such as napthoquinones, vinologous ureas, small nucleic acid fragments (aptamers) and hydrazones show different mechanisms of action (Chung et al., 2010; Gong et al., 2011; reviewed in Jochmans, 2008; Beilhartz & Götte, 2010).”
BackgroundSpecial Issue: Retroviral Enzymes
Menéndez‐Arias, L. (2010) · Viruses · doi:10.3390/v2051181 · Cited by 5
“The role of the HIV-1 RNase H activity in reverse transcription, its structure and catalytic mechanisms, and potential ways to inhibit the enzyme are discussed in the review by Beilhartz and Götte [9].”
Imamichi, T., Chen, Q., Hao, M., Chang, W., & Yang, J. (2022) · Viruses · doi:10.3390/v14122687 · Cited by 5
“62%, Stanford database: 100%, NIAID: 100%, Supplemental Table S3) [36]; thus, we became interested in defining how RH:D109 affects the defective virus.”
BackgroundInfluentialA Computational Model for Predicting RNase H Domain of Retrovirus
Wu, S., Zhang, X., & Han, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161913 · Cited by 5
Martin, J. A., & Palmer, A. G. I. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c11897 · Cited by 4
Wang, J., Li, D., Bambara, R. A., & Dykes, C. (2013) · Journal of General Virology · doi:10.1099/vir.0.054999-0 · Cited by 3
“M41L+T215Y can compensate for the reduced polymerase-dependent RNase H activity of D10K101E+G190S During reverse transcription, RT must degrade the RNA genome after minus-strand synthesis in order for plusstrand synthesis to proceed efficiently (Beilhartz & Götte, 2010).”
Expression of an Mg 2+ -Dependent HIV-1 RNase H Construct for Drug Screening
Farias, R. V., Vargas, D., Castillo, A., Valenzuela, B., Coté, M. L., Roth, M. J., & León, Ó. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00658-11 · Cited by 4
Packing energetics determine the folding routes of the RNase-H proteins.
Yadahalli, S., & Gosavi, S. (2017) · Physical Chemistry, Chemical Physics - PCCP · doi:10.1039/c6cp08940b · Cited by 2
The Discovery and Development of Islatravir (4′‐Ethynyl‐2‐fluoro‐2′‐deoxyadenosine [EFdA], MK‐8591)
Snyder, A. A., Wen, X., Michailidis, E., Kirby, K. A., Mitsuya, H., & Sarafianos, S. G. (2025) · Wiley eBooks · doi:10.1002/9783527845088.ch04 · Cited by 2
Kitagawa, Y., Liao, Z., Morikawa, K., & Oda, M. (2023) · Biophysical Chemistry · doi:10.1016/j.bpc.2023.106961 · Cited by 2
Cilento, M. E., Kirby, K. A., Tedbury, P. R., & Sarafianos, S. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21570-7 · Cited by 2
HIV Biology: Detailed Insight into Virion Structural Organization and Its Pathogenesis
Agrawal, D., Chand, K., Preethi, L., Bhukya, P. L., & Barman, M. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-4480-0_22 · Cited by 1
Gerlits, O. O., Collins, A. J., & Kovalevsky, A. Y. (2026) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2026.100188 · Cited by 2
“…of the reverse transcriptase in human immunodeficiency viruses (HIV-1 and HIV-2), converting the viral single-stranded genomic RNA into the double-stranded proviral DNA, is indispensable for the HIV replication cycle (Tisdale et al., 1991; Beilhartz and G ¨ otte, 2010; Menendez-Arias et al., 2017).”
Characterisation of RT Connection and RNase H Polymorphisms in HIV-1 Subtype C in Botswana
Zuze, B. J. L., Choga, W. T., Moraka, N. O., Choga, O. T., Bhebhe, L. N., Maruapula, D., Phuthego, T., Mokomane, M., Moyo, S. M., & Gaseitsiwe, S. (2026) · Viruses · doi:10.3390/v18040434 · Cited by 1
HIV-1 Reverse Transcriptase Inhibitors: Beyond Classic Nucleosides and Non-Nucleosides
Scarth, B. J., Ehteshami, M., Beilhartz, G. L., & Götte, M. (2011) · Future Virology · doi:10.2217/fvl.11.35 · Cited by 1
Self-citationAltaf, M. (2012) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17003413.v1 · Cited by 2
Development of gold nanoparticle-based antigen delivery platform for vaccines against HIV-1
Lin, F. W. (2015) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-180810-4094 · Cited by 2
Pascual, M. R. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1903.05067 · Cited by 2
Ghafoor, N. A., Baysal, Ö., Süzek, B. E., & Silme, R. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.09.459559 · Cited by 1
Establishment of mammalian cell lines for the production of HIV-1 virus-like particles
Rosengarten, J. F. (2024) · Institutional Repository of Leibniz Universität Hannover (Leibniz Universität Hannover) · doi:10.15488/16390 · Cited by 1
Meanwell, N. A., D’Andrea, S. V., Cianci, C., Dicker, I. B., Yeung, K., Belema, M., & Krystal, M. (2013) · Drug Discovery · doi:10.1002/9781118354483.ch11
Structural & functional characterization of the dengue virus non-structural protein 5 (NS5)
Soh, T. S. (2018) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/73218
Recent Developments in Small Molecular HIV‐1 and Hepatitis B Virus RNase H Inhibitors
Wei, F., Kang, D., Menéndez‐Arias, L., Liu, X., & Zhan, P. (2020) · Wiley eBooks · doi:10.1002/9781119640868.ch9
RNA structural studies : implications in HIV-1 replication and the origins of life
Gremminger, T. (2021) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/90065
The Categories, Mechanisms and Features of Nonnucleoside Reverse Transcriptase Inhibitors of HIV-1
Liu, X. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.6202
Single-molecule tracking of RNA-DNA hybrid removal enzymes important for lagging-strand replication
Foust, D. J., Lowder, F. C., Chung, J., Cresti, J. R., van Gijtenbeek, L. A., Simmons, L. A., & Biteen, J. S. (2026) · Biophysical Journal · doi:10.1016/j.bpj.2026.06.015
Ickler, J. (2021) · DuEPublico (University of Duisburg-Essen) · doi:10.17185/duepublico/74399
Chen, Y. (2012) · theses.fr (ABES) · doi:10.70675/4c961240z22a8z4249z97c3z277d4421df58
“During proteolysis, HIV-1 NC exists in two intermediate forms, NCp15 (partial cleavage product containing NC/SP2/p6) and NCp9 (partial cleavage product containing NC/SP2) and the fully processed form, NCp7.”
InfluentialDéveloppement d'inhibiteurs de la dimérisation du complexe de la Reverse Transcription du VIH-1
Moussa, D. A. (2013) · theses.fr (ABES) · doi:10.70675/a602f295z0cc9z427eza27fzabecdda985bd
RNase H as the New Target for Designing Anti-HIV-1 Drugs: An Overview of Recent Research Progress
Zhao, K., & Meng, G. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_185
Relations structure-fonction du premier transfert de brin chez le vih-1
Maskri, O. (2016) · theses.fr (ABES) · doi:10.70675/f6c5bbd4z0fb6z4f58zbc60z1160695d425b · Cited by 1
DNA vaccination amplifiers HLA-DR cross-restricted public TCR clonotypes shared with HIV controllers
Mukhopadhyay, M. (2017) · theses.fr (ABES) · doi:10.70675/a42f696ez8360z43b6z95a3z984bca393809
Cantaloube-Ferrieu, V. (2023) · theses.fr (ABES) · doi:10.70675/e7422723z7cb9z4feczba3bz407046e4c995
Étude du facteur de transcription ATF5 dans un contexte d'infection par le VIH/VIS
Corne, A. (2024) · theses.fr (ABES) · doi:10.70675/cf074a4fz9249z47bbz9ba3z48dc9cb3d0ce
Structural Basis of Polypurine Track Strand Displacement by HIV-1 Reverse TranscriptasePreprint
Wen, X. R., Lee, R., Muppalla, S. D., McFadden, W. M., Kirby, K. A., Dick, R. A., & Sarafianos, S. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.07.717013
Shahari, M. S. B., Offei, S., Zhang, H., Prahlad, J., Mahoney, J. P., Kirby, K. A., Sarafianos, S. G., & Wang, Z. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110119
BindingDB (2016) · UC San Diego · doi:10.7270/q2w95bwg
Metadata
- Authors
- Beilhartz, G. L., & Götte, M.
- Affiliations
- McGill University (CA)
- Corresponding author
- Götte, Matthias
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2010-03-30
- Volume
- 2
- Issue
- 4
- Pages
- 900-926
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC3185654
- OpenAlex
- W2025259834
- Cited by
- 88
- References
- 108
- Citations by year
- 2026: 6 · 2025: 1 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 8 · 2020: 4 · 2019: 6 · 2018: 7 · 2017: 8 · 2016: 6 · 2015: 2 · 2014: 3 · 2013: 6 · 2012: 8
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- HIV-1, RNase H, reverse transcriptase, catalytic mechanism, enzyme structure, structure-function relationship, RNase H inhibitors, antiviral drug discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.